Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast versus slow transition from stimulant therapy to atomoxetine in pediatric and adolescent ADHD
2008-001767-11Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change in ADHD-RS-IV Parent: Investigator-Administered and Scored at Week 2 and Change in ADHD-RS-IV Parent: Investigator-Administered and Scored at Week 10. Started May 2008; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2008-001767-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001767-11.